{"id":"interrupted-apixaban","_chembl":{"chemblId":"CHEMBL231779","moleculeType":"Small molecule","molecularWeight":"459.51"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Interrupted apixaban","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:39:48.414800+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:39:55.323438+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Interrupted apixaban","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:39:55.658337+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor X inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:39:56.782334+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL231779/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:39:56.432388+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-27T23:49:22.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:39:58.138934+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT06957366","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-01","conditions":"Atrial Fibrillation (AF), VTE","enrollment":920},{"nctId":"NCT05378035","phase":"","title":"DOAC in Chinese Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-09-28","conditions":"Atrial Fibrillation, Stroke, Stroke, Acute","enrollment":427},{"nctId":"NCT04195113","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-08-07","conditions":"Atrial Fibrillation, Venous Thromboembolism, Arterial Vascular Disease","enrollment":242},{"nctId":"NCT03568916","phase":"","title":"Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2016-11","conditions":"Atrial Fibrillation, Ischemic Stroke, Systemic Embolization","enrollment":227579},{"nctId":"NCT02608099","phase":"PHASE4","title":"Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation","status":"COMPLETED","sponsor":"Baim Institute for Clinical Research","startDate":"2015-11","conditions":"Atrial Fibrillation","enrollment":300},{"nctId":"NCT04192552","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Pilot","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2020-01-09","conditions":"Atrial Fibrillation","enrollment":201},{"nctId":"NCT01675076","phase":"PHASE3","title":"Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2013-01","conditions":"Hematoma","enrollment":663},{"nctId":"NCT02228798","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation Study","status":"COMPLETED","sponsor":"McMaster University","startDate":"2014-08-01","conditions":"Atrial Fibrillation","enrollment":3135},{"nctId":"NCT02450682","phase":"PHASE2","title":"Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2016-02","conditions":"Atrial Fibrillation","enrollment":""},{"nctId":"NCT02120560","phase":"PHASE4","title":"Anticoagulation in AF Ablation and Effects on Neurocognitive Function","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2014-07","conditions":"Atrial Fibrillation, Cerebrothromboembolus, Neurocognitive Function","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL231779"},"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Interrupted Eliquis"],"phase":"marketed","status":"active","brandName":"Interrupted apixaban","genericName":"Interrupted apixaban","companyName":"Baim Institute for Clinical Research","companyId":"baim-institute-for-clinical-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:39:58.138934+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}